Juan Brignardello Vela
Juan Brignardello, asesor de seguros, se especializa en brindar asesoramiento y gestión comercial en el ámbito de seguros y reclamaciones por siniestros para destacadas empresas en el mercado peruano e internacional.
Perspective Therapeutics, Inc. is set to showcase promising data on its radiopharmaceutical treatment, [212Pb]VMT-α-NET, at the upcoming ASCO Gastrointestinal Cancers Symposium, scheduled for January 23-25, 2025, in San Francisco, California. The company, which specializes in advanced cancer treatment applications, has announced that an abstract detailing updated interim results from its Phase 1/2a trial has been accepted for a poster presentation. The poster, titled "Interim Safety and Efficacy Data of [Pb]VMT-α-NET in Somatostatin Receptor 2 (SSTR2) Expressing Neuroendocrine Tumors (NETs)," will be presented on January 24, 2025, as part of the symposium's session focused on cancers of the pancreas, small bowel, and hepatobiliary tract. This presentation is particularly significant as it aims to shed light on the safety and efficacy of the treatment in a specific cohort of patients battling neuroendocrine tumors, which can be notoriously difficult to treat. The lead investigator, Dr. Richard L. Wahl, a prominent figure in the field of radiology from the Mallinckrodt Institute of Radiology at Washington University in St. Louis, will be participating in the presentation alongside members of Perspective's management team. Following the presentation, a live question-and-answer session will give attendees an opportunity to engage directly with the researchers, fostering a deeper understanding of the study's findings and implications. Perspective Therapeutics continues to make strides in the field of radiopharmaceuticals, leveraging proprietary technology that utilizes the alpha-emitting isotope Lead-212 (Pb) to deliver targeted radiation to cancer cells. This innovative approach is part of a broader "theranostic" strategy, combining therapy and diagnostics to both visualize and treat tumors effectively, thereby optimizing patient outcomes while minimizing potential side effects. The company’s ongoing clinical trials, including those for metastatic melanoma and neuroendocrine tumors, aim to demonstrate the effectiveness of their treatments at several leading academic institutions. Perspective has also developed a specialized Pb generator to ensure a consistent supply of isotopes necessary for their clinical and commercial endeavors. As the medical community eagerly awaits the unfolding of these results, the implications for patients suffering from neuroendocrine tumors could be substantial. If successful, [212Pb]VMT-α-NET may represent a significant advancement in targeted cancer therapies, offering new hope for those facing these challenging diagnoses. Perspective Therapeutics will also host a conference call on January 24, 2025, at 8:00 AM ET to discuss the findings in greater detail, further engaging with investors and healthcare professionals interested in the future of cancer treatment options. As we look to the future, the journey of Perspective Therapeutics is a testament to the innovative spirit in the fight against cancer, illustrating the potential of cutting-edge research to transform patient care. The upcoming symposium promises to be a pivotal moment for both the company and the broader field of oncology.